Journals / İstanbul Medical Journal / 2014 / Cilt: 15 - Sayı: 1

Late Onset Retroperitoneal Hemorrhage Associated with Cephoperazone-Sulbactam: Case Report

Sefoperazon-Sulbaktam Kullanımına Bağlı Geç Dönemde Gelişen Retroperitoneal Hemoraji: Olgu Sunumu

Pages
82–83
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With this case report, coagulation problems and serious bleeding disor- ders must be kept in mind with cephaperazone usage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Generally, cephaperazone is an effective class of antibiotic that can be used safely at any level of renal function deterioration.
📊
Key Findings & Data:Our patient was a 73 year-old man with acute kidney injury and renal biopsy was performed for the etiology.
💡
Conclusion & Impact:With this case report, coagulation problems and serious bleeding disor- ders must be kept in mind with cephaperazone usage.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Generally, cephaperazone is an effective class of antibiotic that can be used safely at any level of renal function deterioration. The most serious side effect with these antibiotics is bleeding disorders. Our patient was a 73 year-old man with acute kidney injury and renal biopsy was performed for the etiology. Because of urinary tract infection he was using cephap- erazone/sulbactam. Before the biopsy procedure, coagulation parameters- platelet count and prothrombin time / international normalized ratio (INR)- were all checked as normal. Seven days after the biopsy, the hemo- globin level of the patient started to decline. Abdominal ultrasonography was performed and retroperitoneal bleeding was detected. INR was 5,8 when coagulation parameters were checked, We did not find any reason for a coagulation parameter change other than cephaperazone usage. With this case report, coagulation problems and serious bleeding disor- ders must be kept in mind with cephaperazone usage.

Özet

Sefepreazon çeşitli düzeylerde böbrek fonksiyon bozukluğu olan hastalarındagenel olarak güvenle kullanılabilen etkili bir antibiyotiktir. Bu grupantibiyotiklerin en ciddi yan etkileri kanamaya neden olabilmeleridir. Yetmişüç yaşında erkek hastaya böbrek yetmezliği nedeni ile renal biyopsiyapıldı. Hasta üriner sistem enfeksiyonu nedeni ile sefoperazon-sulbaktamkullanmaktaydı. Biyopsi öncesinde hastanın trombosit sayısı ve INRdüzeyleri normal aralıkta idi. Biyopsiden 7 gün hastanın hemoglobin düzeylerindedüşme olması nedeniyle bakılan abdominal ultrasonografideretroperitoneal hematom saptandı. Hastanın INR düzeyinin 5.8 olduğugörüldü. Sefoperazon kullanımı dışında koagulasyon bozukluğuna nedenolabilecek bir neden saptanmadı. Bu vaka raporu ile, sefoperazon kullanımındakoagulasyon bozukluğu gelişebileceği ve buna bağlı olarak ciddikanamalar görülebileceği akılda tutulmalıdır.

🔖

Cite This Article

DEDE, F., ÖZKAYAR, N., TURGUT, D., ÇOŞKUN, E. Y., KOÇ, E., PİŞKİNPAŞA, S. (2022). Late Onset Retroperitoneal Hemorrhage Associated with Cephoperazone-Sulbactam: Case Report. İstanbul Medical Journal, Cilt: 15 - Sayı: 1, 82–83. https://ajindex.com/articles/552218

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990; 88: 38-44. [CrossRef] Lipsky JJ. N-methyl-thio-tetrazole inhibition of the gamma carboxy- lation of glutamic acid: possible mechanism for antibiotic-associated hypoprothrombinaemia. Lancet 1983; 2: 192-3. [CrossRef] Matsubara T, Touchi A, Harauchi T, Takano K, Yoshizaki T. Depression of liver microsomal vitamin K epoxide reductase activity associated with antibiotic-induced coagulopathy. Biochem Pharmacol 1989; 38: 2693-701. [CrossRef] Sattler FR, Weitekamp MR. Ballard JO Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105: 924-31. [CrossRef] Wong RS, Cheng G, Chan NP, Wong WS, NG MH. Use of cefoperazone still needs a caution for bleeding from inducedvitamin K deficiency. Am J Hematol 2006; 81: 76. [CrossRef] Bodey GP, Elting LS, Narro J, Koller C, O'Brien S, Estey E,Benjamin R. An open trial of cefoperazone plus sulbactam forthe treatment of fever in cancer patients. J Antimicrob Chemother1993; 32: 141-52. [CrossRef] Mueller RJ, Green D, Phair JP. Hypoprothrombinemia associated with cefoperazone therapy. South Med J 1987; 80: 1360-62. [CrossRef] Royer JM, Freysz M, Sgro C, Dupont G, Honnart D. Prolonged bleeding time in 2 patients with acute renal insufficiency during treatment with cefoperazone (2nd generation cephalosporin) Therapie 1988; 43: 485-88.
  2. Andrassy K, Koderisch J, Fritz S, Bechtold H, Sonntag H. Alteration of hemostasis associated with cefoperazone treatment. Infection 1986; 14: 27-31. [CrossRef] Burgess E: Intraperitoneal cefoperazone treatment resulting incoagu- lation abnormality. Perit Dial Int 1990; 10: 180-1. 67